Vicapsys Life Sciences, Inc. (VICP)
1.00
0.00 (0.00%)
USD |
OTCM |
Sep 02, 16:00
Vicapsys Life Sciences Research and Development Expense (TTM) : 0.0043M for March 31, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2026 | 0.0043M |
| March 31, 2025 | 0.0143M |
| December 31, 2024 | 0.0141M |
| September 30, 2024 | |
| June 30, 2024 | |
| March 31, 2024 | |
| December 31, 2023 | |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 |
| Date | Value |
|---|---|
| December 31, 2022 | |
| September 30, 2022 | 0.0236M |
| June 30, 2022 | 0.0205M |
| March 31, 2022 | 0.0254M |
| December 31, 2021 | 0.0177M |
| September 30, 2021 | 0.0154M |
| June 30, 2021 | 0.0154M |
| March 31, 2021 | 0.0104M |
| December 31, 2020 | 0.1022M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 699.56M |
| Oncolytics Biotech, Inc. | 13.11M |
| Sangamo Therapeutics, Inc. | 113.79M |
| Sarepta Therapeutics, Inc. | 783.60M |
| Anixa Biosciences, Inc. | 4.557M |